Isopropyl Alcohol: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 15, 2026🚩 Report this page

Isopropyl Alcohol

Other Antiseptics and Disinfectants

Sold as IRIS · alcohol · Dri-Ear · Isopropyl · Dollar General

US FDAGB MHRACA Health Canada

Drug class: Other Antiseptics and Disinfectants
Availability: Over-the-counter
Routes: Topical, Auricular (Otic), Topical (Hospital/Hc Facilities)
Markets covered: 3
Products on record: 91
FDA reports (12 mo): 2,857

D08AXOther Antiseptics and Disinfectants

Overview

Isopropyl Alcohol is an active pharmaceutical ingredient in the Other Antiseptics and Disinfectants group (D08AX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
US United States	FDA	67	April 29, 2026
GB United Kingdom	MHRA	7	May 15, 2026
CA Canada	Health Canada	17	March 3, 2026

USUnited States· FDA

67 products

Uses

USOfficial regulatory label· revised April 23, 2025[1]

For preparation of the skin prior to injection Indications & Usage Section Updated to match label claim

How to take

GBUnited Kingdom· MHRA

7 products

Uses

GBOfficial regulatory label· revised December 20, 2024[2]

The medicinal product is to be used in subjects aged 1 year and above for disinfection of the skin prior to invasive medical procedures to help reduce bacteria that can potentially cause skin infection.

How to take

CACanada· Health Canada

17 products

17 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].

Brands in Canada (8)

Sources & citations

[1]FDA DailyMed · 00b2c444-8601-4d… · revised April 23, 2025 [PDF]
[2]MHRA (UK) · PL592830001 · revised December 20, 2024
[3]Health Canada (DPD) · 01938983 · revised March 22, 2025
[4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised December 20, 2024[2]

g. erythematous, papular, or maculopapular), pruritus and blisters or application site vesicles. Other local symptoms have included skin burning sensation, pain and inflammation. Frequency unknown: dermatitis, eczema, urticaria, chemical burns in neonates.
Immune disorders:
Frequency unknown: chlorhexidine is known to induce hypersensitivity, including generalised allergic reactions and anaphylactic shock. 4). Common: application site rash, application site erythema, application site vesicles, application site pain and application site pruritus.
Frequency, type and severity of adverse reactions in children are expected to be the same as in adults. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised December 20, 2024[2]

). 5 mL green tinted or colourless solution • 26 mL green tinted solution The choice of applicator size will depend on the type of invasive medical procedure being performed and the preference of the clinician. As this product does not have presentations of smaller volumes, prescribers should use alternate products for disinfection of skin prior to simple invasive procedures that require small volume.
5 (green tinted) 34 cm x 34 cm (1156 cm2) Head, neck and small prep areas 26 (green tinted only) 50 cm x 50 cm (2500 cm2) Large prep areas below the neck • Minor and Major surgical procedures • Implantable device placement • Prosthetic device placement or removal • Midline, peripheral intravascular central catheter (PICC), central venous catheter (CVC) insertion and maintenance • Cardiac catheterization and Cardiac Cath Lab procedure • Interventional Radiology procedures Method of administration Avoid getting solution into hair.
Wet hair is flammable. Hair may take up to 1 hour to dry. It is recommended that the antiseptic solution remain on the skin after the procedure for continued protection. The antiseptic will gradually wear away. If early removal is desired, use soap and water or isopropyl alcohol.
8). 4 Special warnings and precautions for use For external use only on intact skin. The solution is flammable. Do not use electrocautery procedures or other ignition sources until the skin is completely dry. Remove any soaked materials, drapes or gowns before proceeding with the intervention.
Do not use excessive quantities and do not allow the solution to pool in skin folds or under the patient or drip on sheets or other material in direct contact with the patient. Where occlusive dressings are to be applied to areas previously exposed to Soluprep, care must be taken to ensure no excess product is present prior to application of the dressing.
To reduce risk of fire, apply the solution carefully: • Avoid getting solution into hair. Wet hair is flammable. Hair may take up to 1 hour to dry. • Begin draping and/or using electrocautery only after solution is completely dry (minimum of 3 minutes on hairless skin; up to 1 hour in hair) and all wet materials are removed.
Soluprep contains chlorhexidine. Rare but serious allergic reactions have been reported with products containing chlorhexidine. 8) Keep out of eyes, ears and mouth. The solution may cause serious or permanent injury if it comes into contact with these areas.
If contact occurs, rinse immediately and thoroughly with cold water and contact a doctor. The use of chlorhexidine solutions, both alcohol based and aqueous, for skin antisepsis prior to invasive procedures has been associated with chemical burns in neonates.
Based on available case reports and the published literature, this risk appears to be higher in preterm infants, especially those born before 32 weeks of gestation and within the first 2 weeks of life. As the development of the epidermal barrier is a continuous process beyond the first months of life, Soluprep is not recommended in the age group less than 1 year old.
Do not use for lumbar puncture or in contact with the meninges. In addition, direct contact with neural tissue or the middle ear must be avoided. Do not use on open skin wounds, broken or damaged skin or as a general skin cleaner. Prolonged skin contact with alcohol containing solutions should be avoided.
At the first sign of local skin reaction the use of Soluprep should be discontinued. The product is for single use only. 2). Discard the applicator after a single use along with any portion of the solution not required to cover the treatment area.

This is not medical advice. Consult a qualified healthcare professional.